ASH 2022 | Decitabine, venetoclax and ponatinib in patients with advanced CML and Ph+ AML
Jayastu Senapati, MBBS, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on findings from a Phase II study (NCT04188405) of decitabine, venetoclax and ponatinib in patients with chronic myeloid leukemia (CML) in myeloid blast phase (MBP) or Philadelphia-chromosome positive (Ph+) acute myeloid leukemia (AML). The investigational combination therapy was well tolerated and enabled a number of patients to receive stem cell transplant, providing a promising strategy in patients with limited treatment options. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
